Sinopharm Group's earnings have been declining at an average annual rate of -1.7%, while the Healthcare industry saw earnings growing at 4% annually. Revenues have been growing at an average rate of 3.2% per year. Sinopharm Group's return on equity is 7.9%, and it has net margins of 1.2%.
Key information
-1.68%
Earnings growth rate
-1.60%
EPS growth rate
Healthcare Industry Growth
8.50%
Revenue growth rate
3.22%
Return on equity
7.89%
Net Margin
1.24%
Last Earnings Update
31 Mar 2026
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Sinopharm Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
OTCPK:SHTD.F Revenue, expenses and earnings (CNY Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
574,272
7,112
24,532
-17
31 Dec 25
575,168
7,155
24,871
0
30 Sep 25
573,564
7,078
25,640
-23
30 Jun 25
575,824
6,811
26,071
0
31 Mar 25
578,904
7,087
26,441
-8
31 Dec 24
584,508
7,050
26,905
0
30 Sep 24
593,073
8,236
26,918
-65
30 Jun 24
590,346
8,653
26,802
0
31 Mar 24
598,318
8,884
26,981
-25
31 Dec 23
596,570
9,054
26,775
0
30 Sep 23
591,686
8,765
26,639
50
30 Jun 23
591,626
8,936
26,657
0
31 Mar 23
570,067
8,688
25,995
34
31 Dec 22
552,148
8,526
25,346
0
30 Sep 22
546,147
7,914
24,584
84
30 Jun 22
533,403
7,870
24,276
0
31 Mar 22
528,383
7,970
23,884
19
31 Dec 21
521,051
7,759
23,656
0
30 Sep 21
510,091
7,930
24,049
29
30 Jun 21
501,770
7,874
23,652
0
31 Mar 21
474,798
6,956
22,643
42
31 Dec 20
456,415
7,187
21,873
0
30 Sep 20
440,194
6,615
21,135
0
30 Jun 20
427,372
6,174
20,430
0
31 Mar 20
431,976
6,554
20,442
-33
31 Dec 19
425,273
6,251
19,797
0
30 Sep 19
406,394
6,311
18,856
22
30 Jun 19
382,717
6,012
18,128
0
31 Mar 19
360,760
6,087
16,903
11
31 Dec 18
344,526
5,834
16,235
0
30 Sep 18
336,113
5,523
15,420
75
30 Jun 18
334,060
5,606
15,580
0
31 Mar 18
318,414
5,083
14,416
22
31 Dec 17
308,354
5,572
13,353
0
30 Sep 17
288,855
5,217
12,094
0
30 Jun 17
269,356
4,861
10,836
0
31 Mar 17
264,691
4,996
10,875
0
31 Dec 16
258,388
4,635
10,744
0
30 Sep 16
251,401
4,515
10,512
0
30 Jun 16
244,414
4,394
10,279
0
31 Mar 16
234,499
3,885
9,964
0
31 Dec 15
228,673
3,772
9,755
0
30 Sep 15
222,513
3,548
9,504
0
30 Jun 15
216,353
3,323
9,254
0
Quality Earnings: SHTD.F has high quality earnings.
Growing Profit Margin: SHTD.F's current net profit margins (1.2%) are higher than last year (1.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SHTD.F's earnings have declined by 1.7% per year over the past 5 years.
Accelerating Growth: SHTD.F's earnings growth over the past year (0.4%) exceeds its 5-year average (-1.7% per year).
Earnings vs Industry: SHTD.F earnings growth over the past year (0.4%) did not outperform the Healthcare industry 17%.
Return on Equity
High ROE: SHTD.F's Return on Equity (7.9%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/24 01:38
End of Day Share Price
2026/05/22 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sinopharm Group Co. Ltd. is covered by 31 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.